Company registration number 15260788 (England and Wales)
CLINICAL RESEARCH SOLUTIONS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
The Granary
Hones Yard
1 Waverley Lane
Farnham
Surrey
GU9 8BB
CLINICAL RESEARCH SOLUTIONS LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 9
CLINICAL RESEARCH SOLUTIONS LIMITED
COMPANY INFORMATION
- 1 -
Directors
Mr S. Gore
Dr D. Hazell
Miss A. Hazell
(Appointed 20 May 2025)
Miss C. Hazell
(Appointed 20 May 2025)
Mr D. Hazell
(Appointed 20 May 2025)
Company number
15260788
Registered office
Middleton House
Yapton Road
Middleton-on-Sea
West Sussex
PO22 6DU
Accountants
TC Group
The Granary
Hones Yard
1 Waverley Lane
Farnham
Surrey
GU9 8BB
CLINICAL RESEARCH SOLUTIONS LIMITED
BALANCE SHEET
AS AT
31 MARCH 2026
31 March 2026
- 2 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
4
186
-
0
Current assets
Debtors
5
20,966
10,660
Cash at bank and in hand
8,767
8,926
29,733
19,586
Creditors: amounts falling due within one year
6
(18,867)
(19,585)
Net current assets
10,866
1
Total assets less current liabilities
11,052
1
Provisions for liabilities
(56)
-
0
Net assets
10,996
1
Capital and reserves
Called up share capital
8
1
1
Profit and loss reserves
10,995
-
0
Total equity
10,996
1

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

CLINICAL RESEARCH SOLUTIONS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2026
31 March 2026
- 3 -
The financial statements were approved by the board of directors and authorised for issue on 3 August 2026 and are signed on its behalf by:
Mr S. Gore
Director
Company Registration No. 15260788
CLINICAL RESEARCH SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 4 -
1
Accounting policies
Company information

Clinical Research Solutions Limited is a private company limited by shares incorporated in England and Wales. The registered office is Middleton House, Yapton Road, Middleton-on-Sea, West Sussex, PO22 6DU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recover ed.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
4 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

CLINICAL RESEARCH SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 5 -
1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

CLINICAL RESEARCH SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 6 -
1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

CLINICAL RESEARCH SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 7 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
5
2
3
Taxation
2026
2025
£
£
Current tax
UK corporation tax on profits for the current period
(7,117)
-
0
Deferred tax
Origination and reversal of timing differences
56
-
0
Total tax credit
(7,061)
-
0
4
Tangible fixed assets
Computers
£
Cost
At 1 April 2025
-
0
Additions
229
At 31 March 2026
229
Depreciation and impairment
At 1 April 2025
-
0
Depreciation charged in the year
43
At 31 March 2026
43
Carrying amount
At 31 March 2026
186
At 31 March 2025
-
0
CLINICAL RESEARCH SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 8 -
5
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
10,233
7,277
Corporation tax recoverable
7,117
-
0
Other debtors
3,616
3,383
20,966
10,660
6
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
6,450
2,325
Taxation and social security
7,460
1,196
Other creditors
4,957
16,064
18,867
19,585
7
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

Liabilities
Liabilities
2026
2025
Balances:
£
£
Accelerated capital allowances
35
-
Retirement benefit obligations
21
-
56
-
CLINICAL RESEARCH SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
7
Deferred taxation
(Continued)
- 9 -
2026
Movements in the year:
£
Liability at 1 April 2025
-
Charge to profit or loss
56
Liability at 31 March 2026
56

The deferred tax liability set out above is expected to reverse within 12 months and relates to accelerated capital allowances that are expected to mature within the same period.

8
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
0
1
-
0
1
Ordinary A shares of 0.1p each
80
0
-
0
-
0
Ordinary B shares of 0.1p each
380
0
-
0
-
0
Ordinary C shares of 0.1p each
80
0
-
0
-
0
Ordinary D shares of 0.1p each
80
0
-
0
-
0
Ordinary G shares of 0.1p each
380
-
-
-
9
Related party transactions

The company entered into transactions with companies that were under common control.

The company made sales of £1 23,381 and purchases for £10,242 during the year to one company under common control. The company was also recharged expenses of £531 from another company under common control.

At the balance sheet date the company was owed £1 0,233 which is included in Trade debtors and owed £3,600 which is included in Trade creditors with the company under common control.

2026-03-31 2025-04-01 false false true 03 August 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr S. Gore Dr D. Hazell Miss A. Hazell Miss C. Hazell Mr D. Hazell 15260788 2025-04-01 2026-03-31 15260788 bus:Director1 2025-04-01 2026-03-31 15260788 bus:Director2 2025-04-01 2026-03-31 15260788 bus:Director3 2025-04-01 2026-03-31 15260788 bus:Director4 2025-04-01 2026-03-31 15260788 bus:Director5 2025-04-01 2026-03-31 15260788 bus:RegisteredOffice 2025-04-01 2026-03-31 15260788 2026-03-31 15260788 2025-03-31 15260788 core:ComputerEquipment 2026-03-31 15260788 core:ComputerEquipment 2025-03-31 15260788 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 15260788 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 15260788 core:CurrentFinancialInstruments 2026-03-31 15260788 core:CurrentFinancialInstruments 2025-03-31 15260788 core:ShareCapital 2025-03-31 15260788 core:RetainedEarningsAccumulatedLosses 2025-03-31 15260788 core:ShareCapitalOrdinaryShareClass1 2026-03-31 15260788 core:ShareCapitalOrdinaryShareClass1 2025-03-31 15260788 core:ShareCapitalOrdinaryShareClass2 2026-03-31 15260788 core:ShareCapitalOrdinaryShareClass2 2025-03-31 15260788 core:ShareCapitalOrdinaryShareClass3 2026-03-31 15260788 core:ShareCapitalOrdinaryShareClass3 2025-03-31 15260788 core:ShareCapitalOrdinaryShareClass4 2026-03-31 15260788 core:ShareCapitalOrdinaryShareClass4 2025-03-31 15260788 core:ShareCapitalOrdinaryShareClass5 2026-03-31 15260788 core:ShareCapitalOrdinaryShareClass5 2025-03-31 15260788 core:ComputerEquipment 2025-04-01 2026-03-31 15260788 2024-12-01 2025-03-31 15260788 core:UKTax 2025-04-01 2026-03-31 15260788 core:UKTax 2024-12-01 2025-03-31 15260788 core:ComputerEquipment 2025-03-31 15260788 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 15260788 bus:OrdinaryShareClass2 2025-04-01 2026-03-31 15260788 bus:OrdinaryShareClass3 2025-04-01 2026-03-31 15260788 bus:OrdinaryShareClass4 2025-04-01 2026-03-31 15260788 bus:OrdinaryShareClass5 2025-04-01 2026-03-31 15260788 bus:OrdinaryShareClass1 2026-03-31 15260788 bus:OrdinaryShareClass1 2025-03-31 15260788 bus:OrdinaryShareClass2 2026-03-31 15260788 bus:OrdinaryShareClass2 2025-03-31 15260788 bus:OrdinaryShareClass3 2026-03-31 15260788 bus:OrdinaryShareClass3 2025-03-31 15260788 bus:OrdinaryShareClass4 2026-03-31 15260788 bus:OrdinaryShareClass4 2025-03-31 15260788 bus:OrdinaryShareClass5 2026-03-31 15260788 bus:OrdinaryShareClass5 2025-03-31 15260788 bus:EntityHasNeverTraded 2025-04-01 2026-03-31 15260788 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 15260788 bus:FRS102 2025-04-01 2026-03-31 15260788 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 15260788 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 15260788 bus:FullAccounts 2025-04-01 2026-03-31 xbrli:pure xbrli:shares iso4217:GBP